ACRS Live signals | Maximize Profits with Getagraph.com

BUY 103142 min ago

@ $1.220

Issued: 14 Feb 2024 @ 10:55

Return: -2.46%

Previous signal: Feb 14 - 09:47

Previous signal: Sell

Return: 0.00 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States...

Stats
Today's Volume	1.63M
Average Volume	1.09M
Market Cap	84.40M
EPS	$-0.0200 ( 2024-02-29 )
Next earnings date	( $-0.340 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.940
ATR14	$0.00500 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Walker Neal	Buy	9 467	Common Stock
2024-04-01	Walker Neal	Sell	3 224	Common Stock
2024-04-01	Walker Neal	Sell	9 467	Restricted Stock Units
2024-03-01	Walker Neal	Buy	9 466	Common Stock
2024-03-01	Walker Neal	Sell	3 223	Common Stock

INSIDER POWER
77.36
Last 99 transactions
Buy: 2 297 521 \| Sell: 311 390

Volume Correlation

Long: 0.36 (neutral)

Short: 0.54 (weak)

Signal:(29.887) Neutral

Aclaris Therapeutics Inc Correlation

10 Most Positive Correlations
POET	0.958
AACG	0.946
GETVV	0.946
AVIR	0.946
NAKD	0.945
HLIO	0.944
IMPL	0.944
CRTO	0.944
HTCR	0.941
CMMB	0.94

10 Most Negative Correlations
IDCC	-0.95
MPRA	-0.949
TZPSU	-0.947
CEG	-0.945
SLMBP	-0.945
STRA	-0.944
GALT	-0.944
CALB	-0.943
PRAA	-0.942
MEOH	-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aclaris Therapeutics Inc Correlation - Currency/Commodity

0.22
( neutral )

0.47
( neutral )

0.00
( neutral )

0.63
( weak )

Aclaris Therapeutics Inc Financials

Annual	2023
Revenue:	$31.25M
Gross Profit:	$13.17M (42.14 %)
EPS:	$-1.270

Q4	2023
Revenue:	$17.57M
Gross Profit:	$11.14M (63.41 %)
EPS:	$-0.0210

Q3	2023
Revenue:	$9.28M
Gross Profit:	$8.43M (90.86 %)
EPS:	$-0.410

Q2	2023
Revenue:	$1.87M
Gross Profit:	$277 000 (14.82 %)
EPS:	$-0.420

Financial Reports:

No articles found.

Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.